Indication: To reduce the development of drug resistant bacteria and maintain the effectiveness of Cefixime for oral suspension and other antibacterial drugs, Cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data,local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefixime for oral suspension, USP is a cephalosporin antibacterial drug indicated for 1. 5 Uncomplicated Urinary Tract Infections caused by Escherichia coli Proteus mirabilis Otitis media caused by Haemophilus influenzae Moraxella catarrhalis Streptococcus pyogenes Streptococcus pyogenes Streptococcus pneumoniae see CLINICAL STUDIES 14 Pharyngitis and Tonsillitis caused by Streptococcus pyogenes Streptococcus pyogenes Streptococcus pyogenes Acute Exacerbations of Chronic Bronchitis caused by Streptococcus pneumoniae Haemophilus influenzae Uncomplicated Gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae.

Indication: Cephalexin is a cephalosporin antibacterial drug indicated for the treatment of the following infections caused by susceptible isolates of designated bacteria: Respiratory tract infection ( 1. 1 Otitis media ( 1. 2 Skin and skin structure infections ( 1. 3 Bone infections (1. 4) Genitourinary tract infections ( 1. 5 To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, Cephalexin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. 6) Cephalexin is indicated for the treatment of respiratory tract infections caused by susceptible isolates of Streptococcus pneumoniae Streptococcus pyogenes. Cephalexin is indicated for the treatment of otitis media caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis. Cephalexin is indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus Streptococcus pyogenes. Cephalexin is indicated for the treatment of bone infections caused by susceptible isolates of Staphylococcus aureus Proteus mirabilis. Cephalexin is indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, Cephalexin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information is available, this information should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.